Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 384971 for:    ALL
Previous Study | Return to List | Next Study

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04984733
Recruitment Status : Not yet recruiting
First Posted : July 30, 2021
Last Update Posted : July 30, 2021
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
University of Southampton

Brief Summary:
An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is MGMT deficient.

Condition or disease Intervention/treatment Phase
Adenocarcinoma - GEJ Cancer of Esophagus Drug: Temozolomide Drug: Temozolomide 50mg/m2/day Drug: Temozolomide 3 month Drug: Temozolomide 24month Phase 2

Detailed Description:
The aim of the ELEVATE trial is to determine the activity and safety of maintenance TMZ dosing followed by nivolumab treatment to evaluate the potential for a future randomised trial against a standard of care control arm. The rationale to continue TMZ for 3 months or until PD is to evaluate the emergence of mismatch repair deficiency both with and without radiological PD, as clinically relevant MMRd may emerge before radiological progression. This will also reduce the number of patients who drop out due to symptomatic progressive disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: An open-label, single arm, A'Hern single stage phase II design. Patients will receive TMZ priming followed by nivolumab to establish disease control rates.
Masking: None (Open Label)
Masking Description: Open label
Primary Purpose: Treatment
Official Title: An Open Label Single Arm Phase II Trial in Patients With Advanced Unresectable Previously Treated Oesophagogastric Adenocarcinoma Which is MGMT Deficient
Estimated Study Start Date : July 19, 2021
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : November 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment

Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV until progression.

Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression. Patients who progress on TMZ will start monotherapy with nivolumab.

Metronomic TMZ50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until progression. Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths until they progress

Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until 24 months. Patients will remain on combination therapy up to a maximum of 24mths.

Drug: Temozolomide

Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.

Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths.

Other Name: Nivolumab

Drug: Temozolomide 50mg/m2/day
Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
Other Name: Nivolumab

Drug: Temozolomide 3 month
Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
Other Name: Nivolumab

Drug: Temozolomide 24month
Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
Other Name: Nivolumab




Primary Outcome Measures :
  1. Tumour Response to nivolumab [ Time Frame: 24 months ]
    To determine the anti-tumour activity of nivolumab, when given after temozolomide in patients with previously treated advanced oesophagogastric adenocarcinoma which are MGMT methylated.


Secondary Outcome Measures :
  1. The percentage of patients who have achieved response [ Time Frame: 6 months ]

    The Disease control rate determine the effect of TMZ priming followed by nivolumab on disease control rates of patients with previously treated advanced oesophagogastric adenocarcinoma which is MGMT methylated.

    Disease control rate, according to RECIST v1.1 and iRECIST, 6 months after starting nivolumab, and 3 months after starting TMZ, respectively.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  • Patients ≥ 18 years of age
  • Pathologically confirmed advanced unresectable or metastatic OGA
  • MGMT methylation on archival tissue
  • Mismatch repair proficient (MSI-normal or MMR intact)
  • Previously treated with at least 3 months of platinum and fluoropyrimidine based chemotherapy for advanced disease and without evidence of disease progression.
  • Measurable disease per RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Can swallow TMZ capsules
  • Adequate organ function assessed within 7 days before randomization:

    • White blood cell count (WBC) > 1.5 x 109/L
    • Absolute neutrophil count (ANC) > 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Haemoglobin ≥ 90 g/L
    • Measured/calculated creatinine clearance ≥ 60 mL/min (according to Cockroft-Gault formula).
    • Total bilirubin within normal limits (if the patient has documented Gilbert's disease ≤ 1.5 x ULN or direct bilirubin ≤ 1.5 x ULN)
    • Aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤ 1.5 x ULN
  • All toxicities (exception alopecia, and grade 2 fatigue, neuropathy and lack of appetite /nausea) attributed to prior anti-cancer therapy must have resolved to grade 1 (NCI CTCAE version 5.0) or baseline before administration of study drug.
  • Women of childbearing potential (WOCBP) may be included following a confirmed menstrual period and must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)). Pregnancy test must be within 24 hours prior to starting treatment. (A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient).
  • WOCBP should use one highly effective and one effective method of birth control during the study treatment period and for at least 5 months after the last dose of the study treatment.
  • Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 5 months after the last dose of the study treatment.
  • Men who are sexually active with a WOCBP must adhere to contraception during and for a period of 7 months after the last dose of the study treatment.
  • Absence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  • Written informed consent

EXCLUSION CRITERIA

  • Previous treatment with TMZ
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
  • Active central nervous system metastases
  • Candidate for curative surgery
  • Previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry. Adequately treated cervical carcinoma in situ, and localized non-melanoma skin cancer are not exclusion criteria, regardless of timepoint of diagnosis.
  • Active, known, or suspected infectious or autoimmune disease (except for patients with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enrol)
  • Conditions requiring systemic treatment with either corticosteroids (≥ 10 mg daily prednisolone or equivalent) or other immunosuppressive medications within 14 days of study drug administration
  • Interstitial lung disease
  • > Grade 1 peripheral neuropathy
  • Positive test result for HBV or HCV indicating acute or chronic infection
  • Known history of testing positive for HIV or known AIDS
  • Known hypersensitivity to the components or excipients of co-trimoxazole, temozolomide or nivolumab. (Please refer to nivolumab IB and SmPC for TMZ and co-trimoxazole).
  • Known hypersensitivity to dacarbazine (DTIC)
  • Clinically significant abnormal 12-lead ECG. If clinically indicated, cardiac function assessment using either echocardiography or MUGA Scan, if clinically significant the patient is ineligible.
  • In the past 6 months serious cardiac illness or medical condition including but not confined to:

    • History of documented congestive heart failure (CHF)
    • High-risk uncontrolled arrhythmias
    • Angina pectoris requiring antianginal medication
    • Clinically significant valvular heart disease
    • Evidence of transmural infarction
    • Poorly controlled hypertension (e.g. systolic >180mm Hg or diastolic greater than 100mm Hg)
  • Patients with severe liver parenchymal damage
  • Patients with severe renal insufficiency where repeated measurements of the plasma concentration cannot be performed
  • Patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides.
  • Patients with acute porphyria
  • Patients with severe myelosuppression

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04984733


Contacts
Layout table for location contacts
Contact: Elizabeth Smyth 023 81205773 elizabeth.smyth2@nhs.net

Sponsors and Collaborators
University of Southampton
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Elizabeth Smyth Cambridge University
Layout table for additonal information
Responsible Party: University of Southampton
ClinicalTrials.gov Identifier: NCT04984733    
Other Study ID Numbers: 61191
First Posted: July 30, 2021    Key Record Dates
Last Update Posted: July 30, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Southampton:
cancer
Oesophagogastric
Oesophagogastric adenocarcinoma,
MGMT deficient,
O6-methylguanine-DNA-methyltransferase
MGMT protein, human
MGMT methylated
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Esophageal Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Nivolumab
Temozolomide
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action